EP Patent

EP3720442A1 — Inhibiting mutant idh-1

Assigned to Forma Therapeutics Inc · Expires 2020-10-14 · 6y expired

What this patent protects

Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

USPTO Abstract

Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Drugs covered by this patent

Patent Metadata

Patent number
EP3720442A1
Jurisdiction
EP
Classification
—
Expires
2020-10-14
Drug substance claim
No
Drug product claim
No
Assignee
Forma Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.